[New anticoagulants - direct factor Xa-inhibitors]

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Thrombosis Research

Background:

• Direct oral anticoagulants (DOACs) targeting Factor Xa are established antithrombotic agents.
• Rivaroxaban, apixaban, and edoxaban are currently available DOACs.
• Clinical studies have demonstrated the efficacy and safety of these novel oral anticoagulants.

Purpose of the Study:

• To review the clinical use, efficacy, and safety of direct oral Factor Xa-inhibitors.
• To compare DOACs with traditional anticoagulants like vitamin K antagonists and low-molecular-weight heparins.
• To highlight the advantages and disadvantages of DOACs in patient care.

Main Methods:

• Review of clinical trial data for rivaroxaban, apixaban, and edoxaban.
• Analysis of registered indications in the EU and CH.
• Comparison of DOACs with vitamin K antagonists and low-molecular-weight heparins regarding efficacy, safety, and administration.

Main Results:

• Rivaroxaban and apixaban have been extensively studied in large patient cohorts (>60,000 patients).
• DOACs demonstrate non-inferior or superior outcomes compared to traditional anticoagulants.
• DOACs offer simplified dosing (once or twice daily) without the need for laboratory monitoring.

Conclusions:

• Direct oral Factor Xa-inhibitors represent a significant advancement in antithrombotic therapy for appropriate patients.
• Advantages include improved administration and comparable or superior efficacy.
• Disadvantages such as dependence on renal clearance, drug interactions, and lack of a specific antidote require careful patient selection and management.